NewAmsterdam Pharma (NAMS) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's Income towards Parent Company fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
- As of Q3 2025, NewAmsterdam Pharma's Income towards Parent Company stood at -$72.0 million, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Income towards Parent Company ranged from a high of -$16.6 million in Q3 2024 and a low of -$93.8 million during Q1 2024
- Over the past 3 years, NewAmsterdam Pharma's median Income towards Parent Company value was -$44.6 million (recorded in 2023), while the average stood at -$50.9 million.
- Per our database at Business Quant, NewAmsterdam Pharma's Income towards Parent Company skyrocketed by 6468.08% in 2024 and then plummeted by 33254.04% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Income towards Parent Company stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its Income towards Parent Company was -$72.0 million in Q3 2025, compared to -$17.4 million in Q2 2025 and -$39.5 million in Q1 2025.